


The Fluorosome Company

Fluorosome-*trans*-pgp



The Fluorosome Company offers an innovative P-glycoprotein inhibition assay, Fluorosome®-*trans*-pgp. This assay employs the novel Fluorosome® platform for the testing of drug efflux transporters. It is highly specific and provides superior, efficient and cost-effective P-glycoprotein/drug interaction determinations.

www.fluorosome.com

P-glycoprotein is a key drug efflux pump responsible in some cases for poor oral and CNS absorption, drug:drug interactions, as well as multi-drug resistance in tumors. Fluorosome®-*trans*-pgp provides a rapid and sensitive screen for the inhibition of the P-glycoprotein by drugs and drug candidates.

The “White Paper” recently issued by the International Transporter Consortium, formed to propose industry and FDA standards for studies of drug/transporter interactions, lists P-glycoprotein as the most important of the ABC (ATP Binding Cassette) transporters involved in clinical absorption and disposition of drugs (Nature Reviews/Drug Discovery Vol. 9, 2010, pgs. 215-236)

Fluorosome®-*trans*-pgp Inhibitor Assay Advantages

- Specific: Fluorosome®-*trans*-pgp contains only the P-glycoprotein transporter
- Cell-free System: No medium containing drug-binding serum proteins used as with cell-based assays
- Multiwell Plate Format: 96-384 well plates
- Dynamic Range: IC₅₀ determinations over a concentration range of >1000
- No Special Sample Requirements: Non-compound specific - no radiolabel, UV or LC-MS

The Fluorosome Company offers:

P-glycoprotein inhibition testing

Standard testing protocols available as:

- Assays at selected compound concentrations
- 3-point assays, e.g., 100, 10, 1 µM concentrations
- Multipoint IC₅₀ determinations
- Custom testing assays designed to meet your specific needs

Your own in-house Pgp inhibition testing

Fluorosome-*trans*-pgp reagent:

- Requires only an injecting fluorescence plate reader
- Rapid and simple, i.e., a 7 point IC₅₀ can be completed in 6 minutes
- Fully amenable to robotics



For more information contact:

East – Layne Los, PhD., Cell: 719-213-7280
Email: layne@nextgenpharma.com

West – Gary Tye, Cell: 719-337-9550
Email: vgtye@nextgenpharma.com

Rocky Mtn. – Cheryl Hite, Cell: 970-222-3844
Email: cheryl@nextgenpharma.com

Midwest – Bob Schultek, Cell: 216-272-4449
Email: bob@nextgenpharma.com

NextGen Pharma Technologies, Inc.
1235 Lake Plaza Drive, Suite 134,
Colorado Springs, CO 80906
Phone: 719-540-2888 Fax: 719-540-5003